JAMP MODAFINIL

1 Dosing Considerations Cardiovascular • A cardiac evaluation, including an electrocardiogram (ECG), should be obtained for all patients before treatment with JAMP Modafinil is initiated. This is particularly recommended for patients with coronary artery disease, a recent history or myocardial infarction, or unstable angina.

Patients with abnormal findings should receive further evaluation before JAMP Modafinil treatment is considered. See 7 WARNINGS AND PRECAUTIONS, Cardiovascular. 1Pregnant Women). Women of reproductive potential should have a negative pregnancy test within a week prior to starting treatment with modafinil.

4 Drug-Drug Interactions). Alternative or concomitant methods of contraception other than steroidal are recommended for patients treated with JAMP Modafinil, and for two months after discontinuation of JAMP Modafinil. 2 Recommended Dose and Dosage Adjustment Recommended Dose Narcolepsy: The adult daily dosage of JAMP Modafinil (modafinil) for patients with narcolepsy is between 200 to 400 mg, divided between morning and noon doses.

The initial daily dose should be 200 mg in divided doses, increasing in increments of 100 mg as needed and tolerated. The timing should be aimed to coincide with the periods of greatest excessive daytime sleepiness. The second dose should generally be taken no later than the early afternoon to minimize the risk of insomnia.

d. Single doses of 300 mg or more, or total daily doses of more than 400 mg aretherefore not recommended.

Obstructive Sleep Apnea:

In OSA, JAMP Modafinil is indicated as an adjunct to successful standard treatment(s) for the underlying obstruction (see 1 INDICATIONS). For patients with OSA, the adult daily dosage of JAMP Modafinil is 200 mg taken as a single dose in the morning.

Circadian Rhythm Sleep Disorder, Shift Work Type (Shift Work Disorder):

For patients with SWD, the adult daily dosage of JAMP Modafinil is 200 mg taken approximately 1 hour prior to the startof their work shift. Dosage Adjustment Pediatric (<18 years of age) The safety and efficacy of modafinil in children under the age of 18 years has not been established.

1 Pediatrics). Geriatric In geriatric patients, elimination of modafinil and its metabolites may be reduced as a consequence of aging. 3 Pharmacokinetics). 3 Pharmacokinetics). 4 Drug-Drug Interactions). 2 Drug Interactions Overview). 5 Missed Dose JAMP Modafinil PM Page 7 of 44 If a dose is missed, it can be taken when remembered, unless it is close to the time for the next dose.

1 Adverse Reaction Overview The most commonly observed adverse events (5%) associated with the use of modafinil and observed more frequently than placebo treated patients in the placebo controlled clinical studies in primary disorders of sleep and wakefulness were headache, nausea, rhinitis, nervousness, diarrhea, back pain, anxiety, dizziness, dyspepsia, and insomnia.

The adverse event profile was similar across these studies. In the placebo controlled clinical trials, 74 of the 934 patients (8%) who received modafinil discontinued due to an adverse experience compared to 3% of patients that received placebo.

The most frequent reasons for discontinuation that occurred at a higher rate for modafinil than placebo patients were headache (2%), anxiety (1%), nervousness (1%), agitation, chest pain, confusion, depression, dizziness, insomnia, and nausea (each <1%).

2 Clinical Trial Adverse Reactions Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.

Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use. The following table presents the adverse experiences that occurred at a rate of 1% or more and were more frequent in adult patients treated with modafinil than in placebo-treated patients in the principal, placebo-controlled clinical trials.

Table 2:

Incidence of Treatment-Emergent Adverse Experiences in Parallel-Group, Placebo-controlled Clinical Trials1 with Modafinil in Adults with Narcolepsy and Obstructive Sleep Apnea and Circadian Rhythm Sleep Disorder, Shift Work Type (Shift Work Disorder) (200 mg, 300 mg and 400 mg)* Modafinil n=934 (%) Placebo n=567 (%) Body as Whole Headache 34% 23% Back Pain 6% 5% Flu Syndrome 4% 3% Chest Pain 3% 1% Chills 1% 0% Neck Rigidity 1% 0% JAMP Modafinil PM Page 16 of 44 Table 2: Incidence of Treatment-Emergent Adverse Experiences in Parallel-Group, Placebo-controlled Clinical Trials1 with Modafinil in Adults with Narcolepsy and Obstructive Sleep Apnea and Circadian Rhythm Sleep Disorder, Shift Work Type (Shift Work Disorder) (200 mg, 300 mg and 400 mg)* Modafinil n=934 (%) Placebo n=567 (%) Cardiovascular Hypertension 3% 1% Tachycardia 2% 1% Palpitation 2% 1% Vasodilatation 2% 0% Digestive Nausea 11% 3% Diarrhea 6% 5% Dyspepsia 5% 4% Dry Mouth 4% 2% Anorexia 4% 1% Constipation 2% 1% Abnormal Liver Function2 2% 1% Flatulence 1% 0% Mouth Ulceration 1% 0% Thirst 1% 0% Hemic/Lymphatic 1% 0%Eosiniphilia Metabolic/Nutritional 1% 0%Edema Nervous Nervousness 7% 3% Insomnia 5% 1% Anxiety 5% 1% Dizziness 5% 4% Depression 2% 1% Paresthesia 2% 0% Somnolence 2% 1% Hypertonia 1% 0% Dyskinesia3 1% 0% Hyperkinesia 1% 0% Agitation 1% 0% Confusion 1% 0% Tremor 1% 0% Emotional Lability 1% 0% Vertigo 1% 0% Respiratory Rhinitis 7% 6% Pharyngitis 4% 2% Lung Disorder 2% 1% Epistaxis 1% 0% Asthma 1% 0% JAMP Modafinil PM Page 17 of 44 Table 2: Incidence of Treatment-Emergent Adverse Experiences in Parallel-Group, Placebo-controlled Clinical Trials1 with Modafinil in Adults with Narcolepsy and Obstructive Sleep Apnea and Circadian Rhythm Sleep Disorder, Shift Work Type (Shift Work Disorder) (200 mg, 300 mg and 400 mg)* Modafinil n=934 (%) Placebo n=567 (%) Skin/Appendages Sweating 1% 0% Herpes Simplex 1% 0% Special Senses Amblyopia 1% 0% Abnormal Vision 1% 0% Taste Perversion 1% 0% Eye Pain 1% 0% Urogenital Urine Abnormality 1% 0% Hematuria 1% 0% Pyuria 1% 0% * Six double-blind, placebo controlled clinical studies in narcolepsy (200 and 400 mg), OSA (200 and 400 mg) and SWD (200 mg and 300 mg).

, General). There is no evidence that normal levels of alertness can be heightened by modafinil. 1 Clinical Trial Adverse Reactions – Pediatric). JAMP Modafinil is not approved for use in pediatric patients for any indication including AttentionDeficit Hyperactivity Disorder (ADHD).

Serious cutaneous adverse reactions have been reported with modafinil use in pediatric patients (see 7 WARNINGS AND PRECAUTIONS, Skin). 4 Geriatrics). 2 CONTRAINDICATIONS JAMP Modafinil is contraindicated: • In patients who are hypersensitive to modafinil, armodafinil (the R-enantiomer of modafinil; not marketed in Canada) or to any ingredient in the formulation, including any non- medicinal ingredient, or component of the container.

For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. • In patients in agitated states and in patients with severe anxiety. • In women who are pregnant or may become pregnant. 1 Pregnant Women). 1 Dosing Considerations Cardiovascular • A cardiac evaluation, including an electrocardiogram (ECG), should be obtained for all patients before treatment with JAMP Modafinil is initiated.

This is particularly recommended for patients with coronary artery disease, a recent history or myocardial infarction, or unstable angina. Patients with abnormal findings should receive further evaluation before JAMP Modafinil treatment is considered.

See 7 WARNINGS AND PRECAUTIONS, Cardiovascular. 1Pregnant Women). Women of reproductive potential should have a negative pregnancy test within a week prior to starting treatment with modafinil. 4 Drug-Drug Interactions). Alternative or concomitant methods of contraception other than steroidal are recommended for patients treated with JAMP Modafinil, and for two months after discontinuation of JAMP Modafinil.

2 Recommended Dose and Dosage Adjustment Recommended Dose Narcolepsy: The adult daily dosage of JAMP Modafinil (modafinil) for patients with narcolepsy is between 200 to 400 mg, divided between morning and noon doses. The initial daily dose should be 200 mg in divided doses, increasing in increments of 100 mg as needed and tolerated.

JAMP

Modafinil is contraindicated: • In patients who are hypersensitive to modafinil, armodafinil (the R-enantiomer of modafinil; not marketed in Canada) or to any ingredient in the formulation, including any non- medicinal ingredient, or component of the container.

For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. • In patients in agitated states and in patients with severe anxiety. • In women who are pregnant or may become pregnant. 1 Pregnant Women).